Navigation Links
Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Date:5/7/2009

-- Management to host call and webcast today at 5:00 p.m. Eastern to discuss financial results and recent business highlights --

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced unaudited financial results for the three months ended March 31, 2009.

Three Months Ended March 31, 2009

As of March 31, 2009, Orexigen held $19.8 million in cash and cash equivalents and an additional $44.9 million in investment securities, available-for-sale.

For the three months ended March 31, 2009, Orexigen reported a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, as compared to a net loss of $23.2 million, or $0.73 per share attributable to common stockholders, for the comparable period in 2008.

Total operating expenses for the three months ended March 31, 2009 were $19.1 million compared to $24.0 million for the comparable period in 2008. The decreased operating expenses were due primarily to a decrease of $5.9 million in research and development expenses in connection with the Company's Contrave(R) Phase 3 clinical trials, related proprietary product formulation work and consulting activities, partially offset by an increase in salaries and personnel related costs. In addition, general and administrative expenses increased approximately $46,000 due primarily to an increase in salaries and personnel related costs.

"This is a momentous time for Orexigen," said Michael Narachi, President and CEO. "We are collecting the last of our patient data for the Contrave Phase 3 development program. We believe that if the data is positive, Contrave should have the ability to address a tremendously underserved obesity market. W
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
2. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
3. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
4. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
8. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
9. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
10. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
11. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... study published today in the journal PNAS (Proceedings ... that time of day and sleep deprivation have a ... crucial when looking at the best time of day ... disease, and for administering medicines effectively. , Researchers from ... Research, London, investigated the links between sleep deprivation, body ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and ... on a single charge with the help of a ... material to replace the graphite traditionally used in one ... 10 times the energy storage capacity of graphite. A ... electrode was published today in Nature Communications . ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3University of Illinois study advances limits for ultrafast nano-devices 2
... 32% Over Second Quarter 2007, - EPS of $0.63 per Basic Share, ... Charges of $1.36 per Basic Share, Increase of ... 56% Over Second Quarter 2007, SILVER ... announced its results of,operations for the quarter ended June 30, 2008., ...
... Granted in ... 2007, Expanding Commercial Protection, LONDON, July 31 ... biotechnology company, today announced that,the United States Patent and ... The Patent Office issued a ,Notice of,Allowance, for patent ...
... known that yeast, the humble ingredient that goes into our ... others. Glucose, their favorite food, provides more energy than any ... to ensure that they consume as much glucose as possible ... identified a previously unknown mechanism that allows yeast to shut ...
Cached Biology Technology:United Therapeutics Reports Second Quarter 2008 Financial Results 2United Therapeutics Reports Second Quarter 2008 Financial Results 3United Therapeutics Reports Second Quarter 2008 Financial Results 4United Therapeutics Reports Second Quarter 2008 Financial Results 5United Therapeutics Reports Second Quarter 2008 Financial Results 6Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent 2Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent 3Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent 4New yeast trick for eating favorite food: Details in Nature paper 2New yeast trick for eating favorite food: Details in Nature paper 3
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2Baboons groom early in the day to get benefits later 2
... cancer researchers have discovered a process that may explain ... one day lead to new therapies that prevent defective ... reported June 8 in the advance online issue of ... Biology Organization (EMBO). , Tumor cells that grow aggressively ...
... that genes control traits such as eye and hair color. ... found that the genes of one organism not only control ... of thousands of other organisms in a community. , ... an entire ecosystem. , "We're pushing a whole new field ...
... are leading a nationwide clinical trial to determine whether ... treatment for early-stage breast cancer. , "By using ... tumor will respond to chemotherapy, we're hoping to more ... hormonal therapy alone and which patients will truly benefit ...
Cached Biology News:MIT sheds light on how tumor cells form 2It's all in the genes 2It's all in the genes 3New genetic test for breast cancer 2
... Thermo Savant SpeedVac Concentrators set the standard ... SC110A SpeedVac uses a combination of centrifugal force, ... a single run., SC110A comes equipped with:, , ... chemical compatibility , ...
Digital display of time, vacuum and temperature , Dual vacuum control of ramping rate and ultimate level , Comes complete with RH40-12 (40 x 1.5 ml) Rotor and (2) Glass Condensation Flasks. ...
...
... series of vacuum concentrators/centrifugal evaporators offers a ... to rapid and safe concentration of heat-labile ... with oil-free or high vacuum pumps, a ... selection of rotors (eliminating sample loss by ...
Biology Products: